Oncorus (ONCR) Stock Price, News & Analysis

Company Overview

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.

Key Stats

• Today's Range: $0.13 to $0.20
• 50-Day Range: $0.01 to $0.13
• 52-Week Range: $0.01 to $0.47
• Volume: 135,947 shs
• Average Volume: 1.33 million shs
• Market Capitalization: $3.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ONCR Stock Analysis - Frequently Asked Questions

How were Oncorus' earnings last quarter?

Oncorus, Inc. (NASDAQ:ONCR) announced its quarterly earnings results on Monday, May, 22nd. The company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by $0.48.

When did Oncorus IPO?

Oncorus (ONCR) raised $87 million in an initial public offering on Friday, October 2nd 2020. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Jefferies, Evercore ISI and Piper Sandler acted as the underwriters for the IPO.

What other stocks do shareholders of Oncorus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncorus investors own include Enterprise Products Partners (EPD), Aeglea BioTherapeutics (AGLE), Athenex (ATNX), Cheniere Energy (LNG), Atreca (BCEL), Fiserv (FI) and Brigham Minerals (MNRL).

Company Calendar

• Last Earnings: 5/22/2023
• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ONCR
• CUSIP: N/A
• CIK: 1671818
• Web: www.oncorus.com
• Phone: 339-240-3330
• Fax: N/A
• Employees: 64
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.33 per share
• Price / Book: 0.05

Miscellaneous

• Outstanding Shares: 26,090,000
• Free Float: 21,633,000
• Market Cap: $3.29 million
• Optionable: Optionable
• Beta: 3.60